PORT

The phase 2 PORT study is an open-label, randomized, cross-over study which compares safety, tolerability and efficacy, of peripheral or central intravenous administration of melflufen in combination with dexamethasone in patients with relapsed refractory multiple myeloma.

Up to 25 patients who have received at least two prior lines of therapy will be enrolled. The study was fully recruited in April 2021, and top line results was presented in Q3 2021.

Patient recruitment has been completed and the study can be closed with relevant scientific data sets.